Program
PA-001
A development code. Also written as “PG4 vaccine in Buffer 1 with low dose PA-001” and “PG4 in Buffer 1 with high dose PA-001”.
Its studies are mostly in COVID-19, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| PeptiDreamits history only | 10 open or running | phase 1since Mar 17, 2026 | Mar 17, 2026 | none ahead |
| Pfizer | 11 open or running | phase 1since Jul 18, 2025 | Jul 18, 2025 | Oct 21, 2027phase 1 · NCT07086677 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Pfizer only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 18, 2025First study: phase 1 study in Streptococcus PneumoniaeFirst studyNCT07086677 · 380 enrolled · United States
Ahead
- Oct 21, 2027Primary completion: phase 1 study in Streptococcus PneumoniaeNCT07086677
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Pfizer leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07086677Streptococcus Pneumoniae · United States | 1 | Active, not recruiting | Oct 21, 2027 | 380 |
How it is read
Names in the registry
- “PG4 vaccine in Buffer 1 with low dose PA-001”, 1 entry
- “PG4 in Buffer 1 with high dose PA-001”, 1 entry
- “PA-001”, 1 entry
Codes read as this program: PA001.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.